CClinicalTrials.gg
Not yet recruitingNCT07742319HUMANITASUpdated Aug 3, 2026

How Differences in the Composition of Microorganisms in the Soil Affect the Microorganisms in the Human Gut, Through the Vegetables That Grow in it: a Process Pilot Study With Healthy Participants

An interventional study of Low diversity vegetable smoothie and High diversity vegetable smoothie in Pilot Study, sponsored by Leiden University Medical Center. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Leiden University Medical Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

There are two objectives for this clinical trial. The first is to test whether, with the current logistics and study setup it is possible to perform the study well and see where there might be bottlenecks we couldn't predict. The second objective is to investigate the relation between the composition of the microorganisms in the soil, the crops that grow in that soil, and the human gut. During the study participants will drink three vegetable smoothies a day, for two periods of one week. The only difference between the two periods is whether the vegetables come from a farm with a low diversity of microorganisms in the soil or a high diversity. Participants will be asked to give blood samples and turn in fecal samples before and after each period.

Read the detailed description

This randomized, double-blind, crossover pilot study will be used to assess the feasibility of logistics including vegetable delivery and preparation of the intervention product by the participants themselves. Besides feasibility, we will aim to identify live bacteria and fungi present in the intervention product (smoothies) and trace these back in stool samples.

The gut microbiome is also called the "second genome" to which many protective and life-supporting functions have been externalized. It orchestrates the crosstalk between our own cells and environmental metagenome. Diet and food choices can modulate gut microbiome species and functional diversity, but the mechanisms by which this occurs are unclear. The nutritional quality of crops, the crop microbiome and the soil microbiome may therefore all be involved.

Ten participants will be randomized in a cross-over design, with each participant drinking three 150 mL vegetable smoothies per day for two separate intervention weeks (HiDi vs LoDi soil origin, randomized 1 : 1). During the first week, smoothies will be prepared with the vegetables derived from microbiome-enriched soil (HiDi) or microbiome-impoverished soil (LoDi). Vegetables, a blender, and detailed instructions to prepare the smoothies on-site will be delivered to the participant. Each participant is asked to keep a diary (in the form of a daily Castor questionnaire), with special attention to dietary habits and intake. Furthermore, before and after this specified diet week, blood and stool samples will be collected. After a washout period of two weeks, participants will be offered identical meals in a crossover design.

02

Conditions studied

  • Pilot Study

Keywords

  • gut microbiome
  • microbiome
  • cross-over
  • dietary intervention
  • soil-plant-gut axis
  • metagenomics
  • pilot
  • feasibility
  • healthy
  • Smoothie intervention
  • randomized controlled trial
  • soil microbiome
  • stool samples
03

In context

Lead sponsor

Leiden University Medical Center is the lead sponsor of 326 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged 18 to 70 years
  • Written informed consent
  • Inhabitant of Leiden

Exclusion criteria

Exclusion Criteria:

  • Any documented causes of chronic disease
  • Suspicion of or present excessive alcohol use defined as >2 units/day (>14/week)
  • Recent use (\<3 months) of antibiotics
  • Any known food allergy or restriction, or following a vegan/vegetarian diet
  • Use of possible drugs interfering microbiota or recent (\< 3 months) changes in dosages
  • A psychiatric, addictive or any other disorder that compromises the participants ability to understand the study content and to give written informed consent for participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Crops derived from Low followed by High diversity soil

    Participants will be given vegetables, originating from low- or high-microbial diversity soil, to prepare smoothies with. In this arm participants start with vegetables from a low diversity soil, after a washout period of two weeks they will receive vegetables from a high diversity soil.

    Other: Low diversity vegetable smoothie · Other: High diversity vegetable smoothie

  • Active comparator
    Crops derived from High followed by Low diversity soil

    Participants will be given vegetables, originating from low- or high-microbial diversity soil, to prepare smoothies with. In this arm participants start with vegetables from a high diversity soil, after a washout period of two weeks they will receive vegetables from a low diversity soil.

    Other: Low diversity vegetable smoothie · Other: High diversity vegetable smoothie

Interventions

  • OtherLow diversity vegetable smoothie

    Vegetable smoothie prepared with crops grown in low-microbial diversity soil

  • OtherHigh diversity vegetable smoothie

    Vegetable smoothie prepared with crops grown in high-microbial diversity soil

06

What researchers measure

Primary outcomes

  1. Feasibility of logistics of the study protocol: Deliveries

    The percentage of successful deliveries to the participants in the pre-agreed time window.

    Time frame: From start enrollment to the end of treatment at 4 weeks

  2. Feasibility of logistics of the study protocol: Preparation of the intervention product

    Using the Daily diary (Castor questionnaire), successful preparation of the intervention product is assessed.

    Time frame: From the start of the treatment period until the end at 4 weeks

  3. Feasibility of logistics of the study protocol: Recruitment rate

    Number of recruited participants per month until the start of the study.

    Time frame: From the start of recruitment until the start of the study

  4. Tracing back life microorganisms from the smoothie in stool samples

    Life bacteria present in the smoothies will be cultured and sequenced to then compare to feces samples of participants

    Time frame: Day 1, Day 7, Day 22, and Day 28

Secondary outcomes

  1. Participant compliance to the study protocol

    Compliance with the protocol will be assessed through the daily lifestyle diary (in the form of a Castor questionnaire). Which will capture the number of consumed smoothies (≥95.2%) and number of consumed smoothies at the correct time window (≥80%). As well whether the duration and time of exercise (≥80%), duration and time of nighttime sleeping period (≥80%), timing and content of main meals (≥80%) between the two periods are comparable. For each of the parameters the compliance threshold is indicated above. Based on these parameters we will get a percentage of participants that were compliant.

    Time frame: From start enrolment until the end of treatment at the end of 4 weeks

  2. Shifts in gut microbiome composition

    Metagenomics will be performed on feces samples from participants to get an compositional view of the gut microbiome. Samples will be taken at baseline, Day 8, Day 21, and Day 29

    Time frame: Baseline, Day 8, Day 21, and Day 29

  3. Sample completeness

    percentage of complete sampling sets

    Time frame: From start of treatment to the end of treatment at 4 weeks

  4. Asses willingness of participants to create their own intervention product

    Using the Daily diary (Castor questionnaire), the participants are required to fill in their opinion on creating their own intervention product on a daily basis. This is measured on a 10 point scale, with 1 being equal to never wanting to do it again and 10 being equal to enjoying it. There is also an optional open question where participants can justify their answer.

    Time frame: From start treatment to end of treatment at 4 weeks

  5. Differences in phytonutrient levels in serum

    After confirmation of significant changes in gut microbiome composition, phytonutrient levels will be measured in serum. Serum will be collected at Baseline, Day 8, Day 21, and Day 29

    Time frame: Baseline, Day 8, Day 21, and Day 29

07

Study locations

1 site
  • Leids Universitair Medisch Centrum
    Leiden, South Holland 2333ZA, Netherlands
    • Jeroen Maljaars, MD, PhD · Contact · P.W.J.Maljaars@lumc.nl · +31 71 526 9111
    • Jeroen Maljaars, MD, PhD · Principal investigator
08

References and documents

Publications

  • Julious, S.A. (2005), Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut. Statist., 4: 287-291. https://doi.org/10.1002/pst.185
  • Hirt H. Healthy soils for healthy plants for healthy humans: How beneficial microbes in the soil, food and gut are interconnected and how agriculture can contribute to human health. EMBO Rep. 2020 Aug 5;21(8):e51069. doi: 10.15252/embr.202051069. Epub 2020 Jul 31. PubMed 32734701 ↗
  • Blum WEH, Zechmeister-Boltenstern S, Keiblinger KM. Does Soil Contribute to the Human Gut Microbiome? Microorganisms. 2019 Aug 23;7(9):287. doi: 10.3390/microorganisms7090287. PubMed 31450753 ↗
  • Fierer N. Embracing the unknown: disentangling the complexities of the soil microbiome. Nat Rev Microbiol. 2017 Oct;15(10):579-590. doi: 10.1038/nrmicro.2017.87. Epub 2017 Aug 21. PubMed 28824177 ↗
  • David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11. PubMed 24336217 ↗
  • Leeming ER, Louca P, Gibson R, Menni C, Spector TD, Le Roy CI. The complexities of the diet-microbiome relationship: advances and perspectives. Genome Med. 2021 Jan 20;13(1):10. doi: 10.1186/s13073-020-00813-7. PubMed 33472701 ↗
  • Johnson AJ, Zheng JJ, Kang JW, Saboe A, Knights D, Zivkovic AM. A Guide to Diet-Microbiome Study Design. Front Nutr. 2020 Jun 12;7:79. doi: 10.3389/fnut.2020.00079. eCollection 2020. PubMed 32596250 ↗
  • Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vosa U, Mujagic Z, Masclee AAM, Jonkers DMAE, Oosting M, Joosten LAB, Netea MG, Franke L, Zhernakova A, Fu J, Wijmenga C, McCarthy MI. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019 Apr;51(4):600-605. doi: 10.1038/s41588-019-0350-x. Epub 2019 Feb 18. PubMed 30778224 ↗
  • Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014 May;146(6):1564-72. doi: 10.1053/j.gastro.2014.01.058. Epub 2014 Feb 4. PubMed 24503132 ↗
  • Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809. PubMed 22297845 ↗
  • Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008 Apr 17;3(4):213-23. doi: 10.1016/j.chom.2008.02.015. PubMed 18407065 ↗
  • Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012 Mar 16;148(6):1258-70. doi: 10.1016/j.cell.2012.01.035. PubMed 22424233 ↗

Individual participant data

Plan to share: Yes — Metagenomic sequencing data from feces and pythonutrient levels in serum (if available)

Supporting information: Study protocol, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07742319
Lead sponsor
Leiden University Medical Center
Collaborators
Maastricht University
Responsible party
Pieter Maljaars (gastroenterologist, Leiden University Medical Center) — Principal investigator
First posted
Aug 3, 2026
Start date
Aug 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 3, 2026

Study contacts

Jeroen Maljaars, MD, PhD
Contact
P.W.J.Maljaars@lumc.nl
+31 71 526 3575
Maarten Tushuizen, MD, PhD
Contact
M.E.Tushuizen@lumc.nl
+31 71 526 9111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion